Literature DB >> 19075676

CD44 and EpCAM: cancer-initiating cell markers.

Rachid Marhaba1, Pamela Klingbeil, Tobias Nuebel, Irina Nazarenko, Markus W Buechler, Margot Zoeller.   

Abstract

Embryonic stem cells are immortal, can self renew, and differentiate into all cells of the body. The adult organism maintains adult stem cells in regenerative organs that can differentiate into all cells of the respective organ. Virchow's hypothesis that cancer may arise from embryonic-like cells has received strong support, as it was demonstrated that tumors contain few cells, known as cancer stem or cancer-initiating cells (CIC), that account for primary and metastatic tumor growth. CIC are mostly defined by expression of CIC-markers that are associated and correlated with the potential of CIC to grow in xenogeneic mice. CIC marker profiles have been elaborated for many tumors, with several markers as CD24, CD44, CD133, CD166, EpCAM, and some integrins, being expressed by tumors of different histological type. Their function in promoting CIC maintenance and activity is largely unknown. The fate of stem cells, determined by their position, is minutely regulated by few adjacent cells creating a niche. CIC also require a niche, mostly for settlement and growth in distant organs. This so called pre-metastatic niche is initiated by the primary tumor before metastasizing cell arrival. How do CIC prepare the pre-metastatic niche? Cancer cells secrete a matrix that serves a cross-talk with surrounding tissues. Additionally, cancer cells can abundantly deliver exosomes, which function as long-distance intercellular communicators. Studies on a rat pancreatic adenocarcinoma support our hypothesis that tumor-derived matrix and exosomes are the main actors in forming the pre-metastatic niche with CIC markers being engaged in matrix preparation and/or exosome delivery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19075676     DOI: 10.2174/156652408786733667

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  74 in total

Review 1.  Regulation of stem cell plasticity: mechanisms and relevance to tissue biology and cancer.

Authors:  Robert Strauss; Petra Hamerlik; André Lieber; Jiri Bartek
Journal:  Mol Ther       Date:  2012-02-07       Impact factor: 11.454

2.  Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.

Authors:  Ines A Silva; Shoumei Bai; Karen McLean; Kun Yang; Kent Griffith; Dafydd Thomas; Christophe Ginestier; Carolyn Johnston; Angela Kueck; R Kevin Reynolds; Max S Wicha; Ronald J Buckanovich
Journal:  Cancer Res       Date:  2011-04-15       Impact factor: 12.701

Review 3.  Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells.

Authors:  Ugo Testa; Elvira Pelosi; Germana Castelli
Journal:  Med Sci (Basel)       Date:  2018-04-13

4.  CD44v6 dependence of premetastatic niche preparation by exosomes.

Authors:  Thorsten Jung; Donatello Castellana; Pamela Klingbeil; Ines Cuesta Hernández; Mario Vitacolonna; David J Orlicky; Steve R Roffler; Pnina Brodt; Margot Zöller
Journal:  Neoplasia       Date:  2009-10       Impact factor: 5.715

5.  In vitro selection of modified RNA aptamers against CD44 cancer stem cell marker.

Authors:  Nidaa Ababneh; Walhan Alshaer; Omar Allozi; Azmi Mahafzah; Mohammed El-Khateeb; Hervé Hillaireau; Magali Noiray; Elias Fattal; Said Ismail
Journal:  Nucleic Acid Ther       Date:  2013-10-30       Impact factor: 5.486

6.  Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors.

Authors:  Puja Gaur; Eric L Sceusi; Shaija Samuel; Ling Xia; Fan Fan; Yunfei Zhou; Jia Lu; Federico Tozzi; Gabriel Lopez-Berestein; Pablo Vivas-Mejia; Asif Rashid; Jason B Fleming; Eddie K Abdalla; Steven A Curley; Jean-Nicolas Vauthey; Anil K Sood; James C Yao; Lee M Ellis
Journal:  Gastroenterology       Date:  2011-07-30       Impact factor: 22.682

7.  Colon cancer stem cells: Potential target for the treatment of colorectal cancer.

Authors:  Riya Gupta; Lokesh Kumar Bhatt; Thomas P Johnston; Kedar S Prabhavalkar
Journal:  Cancer Biol Ther       Date:  2019-05-03       Impact factor: 4.742

8.  Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells.

Authors:  Daniel A Vallera; Bin Zhang; Michelle K Gleason; Seunguk Oh; Louis M Weiner; Dan S Kaufman; Valarie McCullar; Jeffrey S Miller; Michael R Verneris
Journal:  Cancer Biother Radiopharm       Date:  2013-04-23       Impact factor: 3.099

9.  Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells.

Authors:  Ines Herrmann; Patrick A Baeuerle; Matthias Friedrich; Alexander Murr; Susanne Filusch; Dominik Rüttinger; Mariam W Majdoub; Sherven Sharma; Peter Kufer; Tobias Raum; Markus Münz
Journal:  PLoS One       Date:  2010-10-18       Impact factor: 3.240

Review 10.  Pancreatic cancer stem cell markers and exosomes - the incentive push.

Authors:  Sarah Heiler; Zhe Wang; Margot Zöller
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.